scholarly journals Designing of a Multi-epitope Vaccine against the Structural Proteins of Marburg Virus Exploiting the Immunoinformatics Approach

ACS Omega ◽  
2021 ◽  
Author(s):  
Saad Ahmed Sami ◽  
Kay Kay Shain Marma ◽  
Shafi Mahmud ◽  
Md. Asif Nadim Khan ◽  
Sarah Albogami ◽  
...  
RSC Advances ◽  
2021 ◽  
Vol 11 (29) ◽  
pp. 18103-18121
Author(s):  
Ahmad J. Obaidullah ◽  
Mohammed M. Alanazi ◽  
Nawaf A. Alsaif ◽  
Hussam Albassam ◽  
Abdulrahman A. Almehizia ◽  
...  

COVID-19 is caused by SARS-CoV-2, resulting in a contagious respiratory tract infection. For designing a multi-epitope vaccine, we utilized the four structural proteins from the SARS-CoV-2 by using bioinformatics and immunoinformatics analysis.


Author(s):  
A. Semenova ◽  
G. Sivolobova ◽  
A. Grazhdantseva ◽  
S. P’yankov ◽  
O. Taranov ◽  
...  

Based on the highly attenuated vaccinia virus MVA strain, a recombinant variant MVA-GP-VP40-MARV was constructed, which expresses a cassette of the GP and VP-40 genes of the Marburg virus with the formation of immunogenic virus-like particles and protects Guinea pigs from a lethal infection by the Marburg virus.


2008 ◽  
Vol 83 (4) ◽  
pp. 1837-1844 ◽  
Author(s):  
Nolwenn Jouvenet ◽  
Stuart J. D. Neil ◽  
Maria Zhadina ◽  
Trinity Zang ◽  
Zerina Kratovac ◽  
...  

ABSTRACT The expression of many putative antiviral genes is upregulated when cells encounter type I interferon (IFN), but the actual mechanisms by which many IFN-induced gene products inhibit virus replication are poorly understood. A recently identified IFN-induced antiretroviral protein, termed tetherin (previously known as BST-2 or CD317), blocks the release of nascent human immunodeficiency virus type 1 (HIV-1) particles from infected cells, and an HIV-1 accessory protein, Vpu, acts as a viral antagonist of tetherin. Here, we show that tetherin is capable of blocking not only the release of HIV-1 particles but also the release of particles assembled using the major structural proteins of a variety of prototype retroviruses, including members of the alpharetrovirus, betaretrovirus, deltaretrovirus, lentivirus, and spumaretrovirus families. Moreover, we show that the release of particles assembled using filovirus matrix proteins from Marburg virus and Ebola virus is also sensitive to inhibition by tetherin. These findings indicate that tetherin is a broadly specific inhibitor of enveloped particle release, and therefore, inhibition is unlikely to require specific interactions with viral proteins. Nonetheless, tetherin colocalized with nascent virus-like particles generated by several retroviral and filoviral structural proteins, indicating that it is present at, or recruited to, sites of particle assembly. Overall, tetherin is potentially active against many enveloped viruses and likely to be an important component of the antiviral innate immune defense.


Author(s):  
Samira Sanami ◽  
Morteza Alizadeh ◽  
Masoud Nosrati ◽  
Korosh Ashrafi Dehkordi ◽  
Fatemeh Azadegan-Dehkordi ◽  
...  

Author(s):  
Vikrant Singh Rajput ◽  
Ritika Sharma ◽  
Anchala Kumari ◽  
Nidhi Vyas ◽  
Vijay Prajapati ◽  
...  

2020 ◽  
Vol 19 (9) ◽  
pp. 887-898
Author(s):  
Amit Kumar ◽  
Prateek Kumar ◽  
Kumar Udit Saumya ◽  
Shivani K. Kapuganti ◽  
Taniya Bhardwaj ◽  
...  

2020 ◽  
Vol 20 (6) ◽  
pp. 185-193
Author(s):  
Irini Doytchinova ◽  
Andrey Tchorbanov

AbstractThe ongoing COVID-19 pandemic requires urgently specific therapeutics and approved vaccines. Here, the four structural proteins of the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), the causative agent of COVID-19, are screened by in-house immunoinformatic tools to identify peptides acting as potential T-cell epitopes. In order to act as an epitope, the peptide should be processed in the host cell and presented on the cell surface in a complex with the Human Leukocyte Antigen (HLA). The aim of the study is to predict the binding affinities of all peptides originating from the structural proteins of SARS-CoV-2 to 30 most frequent in the human population HLA proteins of class I and class II and to select the high binders (IC50 < 50 nM). The predicted high binders are compared to known high binders from SARS-CoV conserved in CoV-2 and 77% of them coincided. The high binders will be uploaded onto lipid nanoparticles and the multi-epitope vaccine prototype will be tested for ability to provoke T-cell mediated immunity and protection against SARS-CoV-2.


Author(s):  
A.D. Hyatt

Bluetongue virus (BTV) is the type species os the genus orbivirus in the family Reoviridae. The virus has a fibrillar outer coat containing two major structural proteins VP2 and VP5 which surround an icosahedral core. The core contains two major proteins VP3 and VP7 and three minor proteins VP1, VP4 and VP6. Recent evidence has indicated that the core comprises a neucleoprotein center which is surrounded by two protein layers; VP7, a major constituent of capsomeres comprises the outer and VP3 the inner layer of the core . Antibodies to VP7 are currently used in enzyme-linked immunosorbant assays and immuno-electron microscopical (JEM) tests for the detection of BTV. The tests involve the antibody recognition of VP7 on virus particles. In an attempt to understand how complete viruses can interact with antibodies to VP7 various antibody types and methodologies were utilized to determine the physical accessibility of the core to the external environment.


2005 ◽  
Vol 43 (01) ◽  
Author(s):  
M Hoffmann ◽  
P Henneke ◽  
S Weichert ◽  
H Barth ◽  
B Gissler ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document